Cargando…

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events

BACKGROUND: Suboptimal adherence to aspirin therapy for secondary prevention of cardiovascular (CV) events is an important public health problem. Prior studies have demonstrated non-adherent patients are at higher risk of experiencing CV events. OBJECTIVES: This study aimed to estimate the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Djatche, Laurence M., Varga, Stefan, Lieberthal, Robert D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249193/ https://www.ncbi.nlm.nih.gov/pubmed/29691782 http://dx.doi.org/10.1007/s41669-018-0075-2

Ejemplares similares

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
por: Christensen, Mikkel B., et al.
Publicado: (2021)

Challenging the “Divinity” of Aspirin Monotherapy for Secondary Prevention of Cardiovascular Disease
por: Spartalis, Michael, et al.
Publicado: (2023)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events
por: Sylvester, Katelyn W, et al.
Publicado: (2013)

Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke
por: Zhou, Lily W., et al.
Publicado: (2022)

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
por: Jiang, Minghuan, et al.
Publicado: (2019)

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

P2Y(12) inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
por: Aggarwal, Devika, et al.
Publicado: (2022)

Cost‐Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease
por: Michaud, Tzeyu L., et al.
Publicado: (2015)

Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012
por: Mainous, Arch G., et al.
Publicado: (2014)

Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting
por: Carlton, Rashad, et al.
Publicado: (2018)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Aspirin prescribing pattern and guidelines-adherence evaluation for primary prevention of cardiovascular diseases at a teaching hospital
por: Almalki, Salman, et al.
Publicado: (2021)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
por: Amirsadri, Mohammadreza, et al.
Publicado: (2017)

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021)

Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case
por: Djatche, Laurence M., et al.
Publicado: (2018)

Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review
por: Bem, Danai, et al.
Publicado: (2015)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Underutilization of Aspirin Persists in US Ambulatory Care for the Secondary and Primary Prevention of Cardiovascular Disease
por: Stafford, Randall S, et al.
Publicado: (2005)

Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence
por: Khalil, Muhammad Abdul Mabood, et al.
Publicado: (2019)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin use for cardiovascular disease prevention in the uninsured population
por: Liu, Nina, et al.
Publicado: (2020)

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
por: De Berardis, Giorgia, et al.
Publicado: (2007)

Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings
por: Tan, Shi Ying, et al.
Publicado: (2021)

Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study
por: Taliercio, Jonathan J., et al.
Publicado: (2022)

PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
por: Duffy, Danielle, et al.
Publicado: (2014)

Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease
por: Mahtta, Dhruv, et al.
Publicado: (2020)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Publicado: (2010)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
por: De Berardis, Giorgia, et al.
Publicado: (2009)

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
por: Becerra, Virginia, et al.
Publicado: (2015)

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
por: Algra, Ale, et al.
Publicado: (2000)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_atgbkj481r120fosnck9h2629r